Category: Intellectual property
-
New Company to Develop Synthetic Antibody Therapies
A new business is underway to develop and commercialize treatments for Covid-19 and other diseases based on synthetic antibody proteins.
-
Crispr Licensed for Eye Disease Gene Therapies
A developer of inherited eye disease therapies is acquiring rights to the gene editing technology Crispr for treatments that work inside the eyes.
-
Delivery Tech Licensed for CBD Epilepsy Nasal Spray
A company is developing a nasal spray for epilepsy symptoms with a cannabis extract delivered in nanoscale polymer particles to the brain.
-
Biotechs Partner on Agitation Detection Technology
Two developers of treatments and tools for neurological diseases are developing a system for early detection of agitation, a symptom of psychiatric disorders.
-
New Company Forms to Ease Scientific Data Operations
A new company spun off from Harvard University aims to simplify data analysis, management, and collaboration for life science researchers.
-
Pharma Gains Synthetic DNA for Rare Diseases in $1B+ Deal
A French biopharmaceutical company is gaining access to a technology using synthetic nucleic acids to treat rare genetic neurological diseases.
-
Pharma, Biotech Partner on Off-the-Shelf Cell Therapies
A biotechnology enterprise is teaming with a pharmaceutical company to develop off-the-shelf therapies for malfunctioning mitochondria, energy centers of cells.
-
GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal
GlaxoSmithKline and biotechnology company Alector Inc. agreed to co-develop two synthetic antibodies for treating neurodegenerative disorders.
-
Microbiome Drug Candidate Licensed in $525M Deal
A therapy designed to regenerate healthy gut microbes for treating dangerous intestinal infections is licensed for commercialization to Nestlé Health Science.
-
Patent Awarded for Safer Cancer Drug Delivery
A pharmaceutical R&D company is receiving a patent for its process that encapsulates and better targets chemotherapy drugs for cancer patients.